Morgan Stanley resumes Torrid stock coverage with $1.80 target

Morgan Stanley resumed coverage of Torrid Holdings (CURV) with an Equalweight rating and a $1.80 price target versus the stock at $1.82, citing valuation support (InvestingPro fair value $2.20) but a likely long-term spending headwind from GLP-1 anti-obesity adoption. For FY2026 Q1, Torrid beat revenue expectations with net sales of $245.8M (vs. $239.88M, +2.47% surprise) while EPS came in at $0.00 vs. -$0.01, and comparable sales excluding footwear rose 1.2% YoY with overall comps expected to turn positive in the second half. Valuation is ~15x LTM EV/EBITDA (and ~5.5x 2027 EV/EBITDA), which the note says limits multiple compression absent negative earnings revisions.

Analysis

The setup is less about near-term earnings and more about whether a slow-moving demand-shift becomes visible in the P&L before the market has time to digest it. If GLP-1 adoption keeps creeping up, the first leakage should show in unit velocity and promotional intensity, not a clean EBITDA break; that means the stock can look "fine" right up until margin leverage flips negative. The market is implicitly paying for a recovery path, so the key question is whether core apparel can keep comping positive once the footwear bridge fades.

The second-order risk is competitive substitution: consumers reducing discretionary apparel spend are more likely to migrate to broader value channels and off-price rather than stay within the same niche, which pressures traffic quality and inventory turns. That creates a margin problem before a revenue problem, and in a fixed-cost retail model that can force faster de-rating than the headline multiple suggests. The current valuation only looks safe if 2026/27 numbers prove durable; if they do not, the stock can re-rate quickly from "in-line" to structurally challenged.

Contrarian view: consensus may be underestimating the lag between prescription growth and retail spending data. Today’s limited overlap with GLP-1 traffic is backward-looking; once adoption broadens through employer coverage and better accessibility over 6-18 months, the spend effect can show up across household baskets, not just direct user cohorts. What would falsify the bear case is several quarters of positive core comps ex-footwear with stable gross margin and no downward revisions into holiday, which would imply the headwind is either too small or too delayed to matter.

Key Decisions for Investors

• Do not chase CURV on valuation alone; wait for a post-rally entry or higher-volume confirmation before initiating any short. The bear thesis only becomes tradable if core comps ex-footwear weaken or management turns cautious on H2 margin leverage.
• If you need a tactical expression, use a small CURV short vs. XRT long over 1-3 months to isolate idiosyncratic GLP-1 and mix risk from broader retail beta. Risk/reward improves if the stock re-tests recent highs while traffic trends remain merely "stable" rather than accelerating.